Day: December 13, 2022

Mullen Automotive, Inc. Randy Marion Automotive GroupRandy Marion Automotive, one of the Largest and Most Respected Commercial Dealer Groups in the U.S., Signs on to be the First Commercial Dealer to Offer Sales, Service and Parts for Mullen Automotive’s Commercial Lineup, Covering Class 1-6 EV Cargo Vans and Trucks BREA, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces Randy Marion Automotive (“RMA”) as the first dealer group partner for Mullen’s commercial EV lineup, which is set to launch in the U.S. in 2023. Mullen’s commercial EV lineup includes Class 1-3 cargo van and cab chassis offerings and Bollinger Motors Class 4-6 chassis products. “We are impressed with Mullen Automotive’s...

Randy Marion Automotive, one of the largest and most respected commercial dealer groups in the U.S., signs on to be the first commercial dealer to offer sales, service and parts for Mullen Automotive’s commercial lineup, covering Class 1-6 EV cargo vans and trucksRandy Marion Automotive Group First U.S. Dealer Partner for Mullen’s Commercial EV Lineup Mullen Commercial EV’s include Class 1-3 and Bollinger Motors Class 4-6BREA, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces Randy Marion Automotive (“RMA”) as the first dealer group partner for Mullen’s commercial EV lineup, which is set to launch in the U.S. in 2023. Mullen’s commercial EV lineup includes Class 1-3 cargo van...

MALVERN, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, along with the Board of Directors and Executive Management Team, will ring the Nasdaq Closing Bell on Monday, December 19, 2022. The Closing Bell ceremony will be broadcast live starting at 3:45 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. To view the broadcast, please visit https://www.nasdaq.com/marketsite/bell-ringing-ceremony or http://Facebook.com/Nasdaq. “It’s an exciting time at Ocugen as we look back on our 2022 accomplishments and prepare for important clinical and regulatory...

Positive outlook for 2023 with sales now back to pre-COVID levels SAN DIEGO, CALIFORNIA, Dec. 13, 2022 (GLOBE NEWSWIRE) — International Land Alliance, Inc. (OTCQB:ILAL), (“ILAL” or the “Company”), an international land investment and development firm, is pleased to announce a strong close to the year with 10 new home site sales generated during the final tour of 2022 at its Rancho Costa Verde (“RCV”) development. RCV is an 1,100-acre master planned second home, retirement home, and vacation home real estate community located on the east coast of Baja California, Mexico, just south of the small fishing village of San Felipe which is home to over 6,000 retired US citizens. A self-sustained solar powered green community that takes advantage of the advances in solar and other green technology, RCV’s beachfront location, proximity to...

VANCOUVER, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) — NINE MILE METALS LTD. (CSE: NINE, OTCQB: VMSXF, FSE: KQ9) (the “Company” or “Nine Mile”) announces completion of the second tranche of a private placement of approximately $1,200,000 (the “Offering”). The Company issued 1,875,000 flow-through units (each, a “Unit”) at a price of $0.32 per Unit, for proceeds of $600,000. Total proceeds of the offering are now $771,000. Each Unit consists of one flow-through common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”), with each Warrant entitling the holder thereof to purchase one common share at a price of $0.45 for a period of 24 months. In consideration for their services in introducing subscribers to the Company under the Private Placement, finders...

JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau,” or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Company plans to present at the Biotech Showcase™ and host institutional investor meetings at this event, as well as at the LifeSci Partners Corporate Access Event. Both in-person events are taking place in parallel with the 41st Annual J.P. Morgan Healthcare Conference which will be held January 9-12, 2023 in San Francisco, California. Biotech Showcase:Raphi Levy, Chief Financial Officer, will provide an overview of the Company, including its Alpha DaRT technology, recent pre-clinical and clinical progress, and upcoming clinical trials including its U.S. multi-center pivotal trial in...

In December 2022, the 15th patient was dosed with IMX-110 IMX-110 clinical trial data expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110 IMX-110 monotherapy and IMX-110 combination clinical trial with Beigene/Novartis anti-PD-1 tislelizumab enabled by newly manufactured, scaled-up IMX-110 GMP batchesLOS ANGELES, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced patient dosing in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. This is the fifteenth patient dosed with IMX-110 to-date. IMX-110 clinical...

Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model showed superiority to lenalidomide (Revlimid®) Synergistic activity with rituximab in DLBCL mouse model resulted in complete regressions and was superior to the approved regimen, lenalidomide and rituximab Company planning to submit IND and begin a Phase 1 trial in 2023 HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that yesterday Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, presented positive SP-3164 preclinical data at the 64th American Society of Hematology (ASH)...

Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in the first half of the year Strengthens the collaboration between Sharps and Nephron to advance the previously announced Inject-EZ startup in South Carolina in early 2023 NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (the “Company”, “Sharps”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration. “This distribution agreement opens so many possibilities...